References
- Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67:7–30.
- Center MM, Jemal A, Smith RA, et al. Worldwide variations in colorectal cancer. CA Cancer J Clin. 2009;59:366–378.
- Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
- Lao VV, Grady WM. Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol. 2011;8:686–700.
- Boysen AK, Spindler KL, Hoyer M, et al. Metastasis directed therapy for liver and lung metastases from colorectal cancer – a population based study. Int J Cancer. 2018.
- Li Y, Wu H, Wu W, et al. Structural insights into the TRIM family of ubiquitin E3 ligases. Cell Res. 2014;24:762–765.
- Thompson S, Pearson AN, Ashley MD, et al. Identification of a novel Bcl-2-interacting mediator of cell death (Bim) E3 ligase, tripartite motif-containing protein 2 (TRIM2), and its role in rapid ischemic tolerance-induced neuroprotection. J Biol Chem. 2011;286:19331–19339.
- Yin H, Zhu Q, Liu M, et al. GPER promotes tamoxifen-resistance in ER + breast cancer cells by reduced Bim proteins through MAPK/Erk-TRIM2 signaling axis. Int J Oncol. 2017;51:1191–1198.
- Hammoud SS, Cairns BR, Jones DA. Epigenetic regulation of colon cancer and intestinal stem cells. Curr Opin Cell Biol. 2013;25:177–183.
- Ilson DH. Adjuvant therapy in colon cancer: less is more. Lancet Oncol. 2018;19:442–443.
- Tang M, Price TJ, Shapiro J, et al. Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis. Expert Rev Anticancer Ther. 2018;18:339–349.
- Wu C. Systemic therapy for colon cancer. Surg Oncol Clin N Am. 2018;27:235–242.
- Balastik M, Ferraguti F, Pires-da Silva A, et al. Deficiency in ubiquitin ligase TRIM2 causes accumulation of neurofilament light chain and neurodegeneration. Proc Natl Acad Sci USA. 2008;105:12016–12021.
- Khazaei MR, Bunk EC, Hillje AL, et al. The E3-ubiquitin ligase TRIM2 regulates neuronal polarization. J Neurochem. 2011;117:29–37.
- Qin Y, Ye J, Zhao F, et al. TRIM2 regulates the development and metastasis of tumorous cells of osteosarcoma. Int J Oncol. 2018;53:1643–1656.
- Cai J, Maitra A, Anders RA, et al. beta-Catenin destruction complex-independent regulation of Hippo-YAP signaling by APC in intestinal tumorigenesis. Genes Dev. 2015;29:1493–1506.
- Wu LMN, Deng Y, Wang J, et al. Programming of Schwann cells by Lats1/2-TAZ/YAP signaling drives malignant peripheral nerve sheath tumorigenesis. Cancer Cell. 2018;33:292–308 e7.
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.
- Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011;331:1559–1564.
- Peuhu E, Virtakoivu R, Mai A, et al. Epithelial vimentin plays a functional role in mammary gland development. Development. 2017;144:4103–4113.
- Messica Y, Laser-Azogui A, Volberg T, et al. The role of vimentin in regulating cell invasive migration in dense cultures of breast carcinoma cells. Nano Lett. 2017;17:6941–6948.
- Castro-Munozledo F, Meza-Aguilar DG, Dominguez-Castillo R, et al. Vimentin as a marker of early differentiating, highly motile corneal epithelial cells. J Cell Physiol. 2017;232:818–830.
- Snider NT, Ku NO, Omary MB. The sweet side of vimentin. Elife. 2018;7:e35336.